Influenza vaccine demonstrates favourable immunogenicity and tolerability in clinical testing

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary endpoint for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent drifted H1N1 strains. The H1N1 influenza vaccine candidate is based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology.

The clinical trial commenced in May 2013 and completed enrollment and treatment of all 84 healthy volunteers in August 2013. During this trial the volunteers received two injections of the vaccine, 21 days apart. A*STAR and Cytos are pleased to announce that the vaccine was safe and well tolerated No serious adverse events were reported during the trial. The induced immune responses were comparable to those of approved seasonal .

A*STAR is developing the vaccine candidate under a collaborative research, development and commercialisation agreement entered into with Cytos in 2010, with the goal of providing the government of Singapore effective means of combatting influenza epidemics and pandemics. Under the agreement, Cytos retains the worldwide right to develop and commercialise the globally, while A*STAR subsidiaries have the right to develop and commercialise the vaccine for Singapore and other ASEAN countries and can earn royalties on worldwide net sales.

Christian Itin, PhD, Chairman and Chief Executive Officer of Cytos, commented, "We are encouraged to see seroconversion in patients treated with our bacterially derived recombinant and are evaluating next steps with our partner A*STAR. The results of this study further support the utility of our VLP vaccine platform for the treatment of infectious diseases."

Professor Alex Matter, Chief Executive Officer of D3 (Drug Discovery and Development) and A*STAR's Experimental Therapeutics Centre (ETC) said, "We are very pleased with the outcome of this trial. The favourable data demonstrates that the VLP-vaccine strategy is an effective one. We are now planning, in conjunction with Cytos, the next steps for this project."

Related Stories

First influenza vaccine brought to clinical testing

date May 17, 2013

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Two new HIV vaccine candidates: Q&A with Nicolas Mouz

date Nov 27, 2013

European researchers have designed two new vaccine candidates to fight the HIV virus. These have been developed within the EU-funded project EURONEUT 41. They work by targeting the mechanism of HIV entry into the body via ...

New vaccine to fight multiple vaccine strains

date Aug 21, 2008

A universal vaccine effective against several strains of influenza has passed its first phase of testing, according to Dr. Christine Turley of the University of Texas at Galveston.

Recommended for you

Study links adverse childhood experiences to pediatric asthma

date Apr 22, 2015

Robyn Wing, M.D., an emergency medicine physician at Hasbro Children's Hospital, recently led a study that found children who were exposed to an adverse childhood experience (ACE) were 28 percent more likely to develop asthma. ...

How the immune system fights worm infections

date Apr 22, 2015

The immune system can 'remember' infectious invaders. EPFL scientists now show how immune memory triggers the body's ability to repair tissues damaged during worm infections. The work could lead to better ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.